Tab. II.
Basic characteristics of group A, by survival and death
| Group A | Survival (N = 80) |
Death (N = 77) |
P |
|---|---|---|---|
| Age [years] | 56.6 ± 9.0 | 59.4 ± 8.4 | 0.04 |
| HF duration [months] | 24 (12-48) | 55 (16-72) | 0.006 |
| NYHA class | 2 (2-3) | 3 (3-4) | < 0.001 |
| LVEF [%] | 25.9 ± 7.1 | 22.1 ± 6.2 | < 0.001 |
| LA [mm] | 44.6 ± 5.7 | 48.2 ± 7.2 | < 0.001 |
| RVEDd [mm] | 27.4 ± 4.4 | 30.0 ± 5.0 | < 0.001 |
| hs-CRP [mg/l] | 2.56 (1.3-4.11) | 4.58 (2.01-12.1) | < 0.001 |
| Fibrinogen [mg/dl] | 348.5 (324-398.5) | 456 (376-539.5) | < 0.001 |
| NT-proBNP [pg/ml] | 567 (403.1-1026) | 1890 (1230-3240) | < 0.001 |
| eGFR [ml/min/1.73 m2] | 80.3 ± 21.6 | 64.3 ± 25.3 | < 0.001 |
| Uric acid [µmol/l] | 417.3 ± 126.0 | 471.2 ± 146.3 | 0.02 |
| Bilirubin [µmol/l] | 13.4 (10.8-17.8) | 17.5 (12.95-25.5) | < 0.001 |
eGFR – estimated glomerular filtration rate, hs-CRP – high-sensitivity C-reactive protein, LA – left atrium, LVEF – left ventricular ejection fraction, NT-proBNP – N-terminal propeptide of the brain natriuretic peptide, NYHA – New York Heart Association, RVEDd – right ventricular end-diastolic diameter M-mode (diastole)